POSTER PRESENTATION

Open Access

P003. NSAIDs for symptomatic treatment of headache

Giannapia Affaitati^{1*}, Paolo Martelletti², Mariangela Lopopolo¹, Claudio Tana³, Francesca Massimini⁴, Francesco Cipollone¹, Domenico Lapenna¹, Maria Adele Giamberardino¹, Raffaele Costantini⁵

From Abstracts from the 1st Joint ANIRCEF-SISC Congress Rome, Italy. 29-31 October 2015

Background and aims

Clinical observations suggest that the use of non-steroidal anti-inflammatory drugs (NSAIDs) for symptomatic treatment of headache is not in line with recommendations by international guidelines [1]. The aim of the study was to evaluate NSAIDs use for episodic headache at the Headache Centre of the Chieti University in the period: January 2000-February 2013.

Methods

A retrospective evaluation was carried out on 6,443 records of episodic migraine (n=2,330), tension-type headache (TTH) (n=807) and migraine + TTH (n=3,306) sufferers relative to NSAID use for the acute attack: type of NSAID/s; uni- or poly-therapy (one or more NSAID/s in different attacks) and NSAID efficacy (subjective scale: complete (C), partial (P) or absent (A) pain relief at 2 hours), at the first visit and 1-year follow-up.

Results

In migraine patients, 80% had been NSAID users in the past year. The three most frequently employed molecules were: nimesulide (57%), ketoprofen (25%) and ibuprofen (24%). Complete vs. incomplete/absent efficacy was significantly higher for all three (p < 0.0001). NSAIDs were replaced with triptans in 53% of the patients at the first visit; after 1 year: a significant spontaneous return to NSAIDs occurred in 56% of the cases (p < 0.0005) for inadequate efficacy/side effects (62%) or difficulty in obtaining prescription (38%) of triptans from the family doctor. In TTH patients, 90% were

¹Headache Centre, Department of Medicine and Science of Aging, "G. D'Annunzio" University of Chieti, Chieti, Italy

Full list of author information is available at the end of the article



NSAID users; preferences were: nimesulide (48%), ketoprofen (47%) and diclofenac (19%); complete vs. incomplete/absent efficacy was significantly higher for the first two (p < 0.02). Replacement with analgesics was performed in 24% of the patients at the first visit; at oneyear follow-up a spontaneous return to NSAIDs occurred in 29% of the cases for inadequate efficacy of the non-NSAID therapy. In Migraine + TTH patients who were not able to distinguish the nature of their attack at the beginning of the pain, 89% were NSAID users; the three most frequently employed molecules were: nimesulide (44%), ibuprofen (42%) and ketoprofen (38%); complete vs. incomplete/absent efficacy was significantly higher for all three (0.001 .Replacement with analgesics was prescribed to 31% of the patients at the first visit; at one-year follow-up a spontaneous return to NSAIDs occurred in 37% of them for inadequate efficacy of the non-NSAID therapy.

Conclusions

NSAID use in episodic headache is higher than could be hypothesized based on guidelines [2]. NSAID role/efficacy, particularly in migraine, should be better understood. A higher degree of sensitization towards different treatment options for headache should also be promoted in the medical environment [3].

Written informed consent to publish was obtained from the patient(s).

Authors' details

¹Headache Centre, Department of Medicine and Science of Aging, "G. D'Annunzio" University of Chieti, Chieti, Italy. ²Department of Clinical and Molecular Medicine, Regional Referral Headache Centre, "Sant'Andrea" Hospital, "Sapienza" University, Rome, Italy. ³Internal Medicine Unit, Guastalla Hospital, AUSL Reggio Emilia, Reggio Emilia, Italy. ⁴Institute of Clinical Pathology, "G. D'Annunzio" University of Chieti, Chieti, Italy. ⁵Institute of Surgical Pathology, "G. D'Annunzio" University of Chieti, Chieti, Italy.

© 2015 Affaitati et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/) applies to the data made available in this article, unless otherwise stated.

^{*} Correspondence: gp@unich.it

Published: 28 September 2015

References

- 1. Silberstein SD, Stirpe JC: COX inhibitors for the treatment of migraine. Expert Opin Pharmacother 2014, **15(13)**:1863-1874.
- Motola D, Vaccheri A, Silvani MC, Poluzzi E, Bottoni A, De Ponti F, Montanaro N: Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur J Clin Pharmacol 2004, 60(10):731-738.
- Taylor FR, Kaniecki RG: Symptomatic treatment of migraine: when to use NSAIDs, triptans, or opiates. Curr Treat Options Neurol 2011, 13(1):15-27.

doi:10.1186/1129-2377-16-S1-A162

Cite this article as: Affaitati *et al.*: P003. NSAIDs for symptomatic treatment of headache. *The Journal of Headache and Pain* 2015 16(Suppl 1):A162.

Submit your manuscript to a SpringerOpen[●] journal and benefit from:

- ► Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- ► High visibility within the field
- ► Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com